Mustang Bio (MBIO) Reports Preclinical Data on Regional Delivery of MB-103 HER2 CAR T Cells to Target HER2+ …StreetInsider.comMustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel … Continue reading
Intellia Therapeutics Announces Third Quarter 2017 Financial ResultsGlobeNewswire (press release)CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on developing curat… Continue reading
pharmaphorum |
Novartis files CAR–T in lymphoma, sets up rivalry with Gilead
pharmaphorum The new US filing announced today means Novartis is pursuing approval in relapsed/refractory diffuse large B-cell (r/r DLBCL) lymphoma patients ineligible for autologous stem cell transplant. Kymriah was the first CAR–T drug to gain US approval in … Novartis asks FDA to expand Kymriah’s use against blood cancerNasdaq Novartis submits application to FDA for KymriahTM (tisagenlecleucel …GlobeNewswire (press release) Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCLMarkets Insider PMLiVE –The Pharma Letter all 16 news articles » |
Nasdaq |
Novartis asks FDA to expand Kymriah’s use against blood cancer
Nasdaq With CAR–T therapies, patients’ immune cells are taken from their bodies, genetically re-engineered to fight their cancer and then reinfused. Novartis has set the price for Kymriah at $475,000 for young patients with ALL, but the Basel-based company … Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking …GlobeNewswire (press release) |
|
Researchers uncover surprising immune cell activity that may explain limitations of immunotherapy
News-Medical.net Researchers have uncovered a surprising process within a key immune cell that may help explain the limitations of immunotherapy as a cancer treatment. Treg cells work within the immune system to suppress immune function. It’s a normal process: T cells … |
|
Researchers uncover surprising immune cell activity that may explain limitations of immunotherapy
News-Medical.net Researchers have uncovered a surprising process within a key immune cell that may help explain the limitations of immunotherapy as a cancer treatment. Treg cells work within the immune system to suppress immune function. It’s a normal process: T cells … |